Daiichi Sankyo Co., Ltd.

73 clinical trials · Sponsor

Record	Firm	Date
A Study of DS-1471a In Subjects With Advanced Solid Tumors (NCT06074705)	Daiichi Sankyo Co., Ltd.	2023-08-04
Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia (NCT05606094)	Daiichi Sankyo Co., Ltd.	2023-03-09
Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects (NCT04914520)	Daiichi Sankyo Co., Ltd.	2021-06-11
Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects (NCT04818398)	Daiichi Sankyo Co., Ltd.	2021-04-01
A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan (NCT04703322)	Daiichi Sankyo Co., Ltd.	2021-03-15
Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects (NCT04821674)	Daiichi Sankyo Co., Ltd.	2021-03-15
A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT (NCT04488822)	Daiichi Sankyo Co., Ltd.	2020-09-25
A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants (NCT04459598)	Daiichi Sankyo Co., Ltd.	2020-08-19
A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma (NCT04458272)	Daiichi Sankyo Co., Ltd.	2020-07-08
Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy (NCT04433234)	Daiichi Sankyo Co., Ltd.	2020-06-30
Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis (NCT04211415)	Daiichi Sankyo Co., Ltd.	2020-01-13
Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma (NCT04102150)	Daiichi Sankyo Co., Ltd.	2019-11-21
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain (NCT04094662)	Daiichi Sankyo Co., Ltd.	2019-09-18
Study of Mirogabalin for Central Neuropathic Pain (NCT03901352)	Daiichi Sankyo Co., Ltd.	2019-03-12
Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) (NCT03723681)	Daiichi Sankyo Co., Ltd.	2018-11-05
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (NCT03599518)	Daiichi Sankyo Co., Ltd.	2018-09-21
Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT03671564)	Daiichi Sankyo Co., Ltd.	2018-08-23
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) (NCT03384940)	Daiichi Sankyo Co., Ltd.	2018-02-23
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) (NCT03401385)	Daiichi Sankyo Co., Ltd.	2018-01-31
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors (NCT03383692)	Daiichi Sankyo Co., Ltd.	2018-01-12
Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer (NCT03366428)	Daiichi Sankyo Co., Ltd.	2017-12-26
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01] (NCT03329690)	Daiichi Sankyo Co., Ltd.	2017-11-02

Track Daiichi Sankyo Co., Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.